Tags

Type your tag names separated by a space and hit enter

Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma.
Med Oncol. 2019 Jan 21; 36(2):21.MO

Abstract

BACKGROUND

No predictive biomarker of immune checkpoint inhibitors in head and neck squamous cell carcinoma (HNSCC) has been well established. The impact of programmed death-ligand 1 (PD-L1) expression, CD8+ tumor-infiltrating lymphocytes (TILs), and p16 status in HNSCC is unclear and may vary according to ethnicity.

METHODS

HNSCC patients treated between 2007 and 2013 were reviewed. Archival tissues were retrieved for PD-L1, CD8+ TILs, and p16 analyses. PD-L1 expression was evaluated by using the validated SP142 assay on the VENTANA platform. CD8+ TILs were defined by using semiquantitative scoring.

RESULTS

A total of 203 patients were analyzed. PD-L1 expression was observed in 80% of patients and was significantly associated with older age (P < 0.001). A high CD8+ TIL score (≥ 6) was significantly associated with never-smoking (P = 0.020), oral cavity cancer (P < 0.001), and stage M0 at presentation (P = 0.025). The p16 status was positive in 12% of patients. Patients with a high TIL score had a significantly longer OS (P = 0.032). Patients with PD-L1 expression of 1-49% and ≥ 50% were associated with a significantly shorter OS compared with those with PD-L1 < 1% (P = 0.027 and P = 0.011, respectively). Multivariate analysis showed that PD-L1 ≥ 50% was significantly associated with a poor OS. (HR 2.98 [95% CI 1.2-7.39]; P = 0.019.) CONCLUSIONS: A high prevalence of PD-L1 expression was observed in HNSCC using the validated SP142 assay. PD-L1 expression was associated with older age, while highly PD-L1 expression (≥ 50%) was an independent prognostic factor for poor OS in anti-PD1/PD-L1 untreated HNSCC patients.

Authors+Show Affiliations

Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand. nuttapong.nga@mahidol.ac.th.Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand.Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand.Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.Ramathibodi Research Center, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.Division of Radiation Oncology, Department of Radiology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.Division of Medical Oncology, Department of Medicine, Faculty of Medicine Ramathibodi Hospital, Mahidol University, 270 Rama VI Road, Ratchathewi, Bangkok, 10400, Thailand.Department of Pathology, Faculty of Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

30666437

Citation

Ngamphaiboon, Nuttapong, et al. "Characteristics and Impact of Programmed Death-ligand 1 Expression, CD8+ Tumor-infiltrating Lymphocytes, and P16 Status in Head and Neck Squamous Cell Carcinoma." Medical Oncology (Northwood, London, England), vol. 36, no. 2, 2019, p. 21.
Ngamphaiboon N, Chureemas T, Siripoon T, et al. Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Med Oncol. 2019;36(2):21.
Ngamphaiboon, N., Chureemas, T., Siripoon, T., Arsa, L., Trachu, N., Jiarpinitnun, C., Pattaranutaporn, P., Sirachainan, E., & Larbcharoensub, N. (2019). Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. Medical Oncology (Northwood, London, England), 36(2), 21. https://doi.org/10.1007/s12032-018-1241-1
Ngamphaiboon N, et al. Characteristics and Impact of Programmed Death-ligand 1 Expression, CD8+ Tumor-infiltrating Lymphocytes, and P16 Status in Head and Neck Squamous Cell Carcinoma. Med Oncol. 2019 Jan 21;36(2):21. PubMed PMID: 30666437.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Characteristics and impact of programmed death-ligand 1 expression, CD8+ tumor-infiltrating lymphocytes, and p16 status in head and neck squamous cell carcinoma. AU - Ngamphaiboon,Nuttapong, AU - Chureemas,Teeranuch, AU - Siripoon,Teerada, AU - Arsa,Lalida, AU - Trachu,Narumol, AU - Jiarpinitnun,Chuleeporn, AU - Pattaranutaporn,Poompis, AU - Sirachainan,Ekaphop, AU - Larbcharoensub,Noppadol, Y1 - 2019/01/21/ PY - 2018/10/25/received PY - 2018/12/19/accepted PY - 2019/1/23/entrez PY - 2019/1/23/pubmed PY - 2019/4/26/medline KW - CD8+ tumor infiltrating lymphocytes KW - Head and neck squamous cell carcinoma KW - Human papillomavirus KW - P16 KW - Programmed death ligand-1 SP - 21 EP - 21 JF - Medical oncology (Northwood, London, England) JO - Med Oncol VL - 36 IS - 2 N2 - BACKGROUND: No predictive biomarker of immune checkpoint inhibitors in head and neck squamous cell carcinoma (HNSCC) has been well established. The impact of programmed death-ligand 1 (PD-L1) expression, CD8+ tumor-infiltrating lymphocytes (TILs), and p16 status in HNSCC is unclear and may vary according to ethnicity. METHODS: HNSCC patients treated between 2007 and 2013 were reviewed. Archival tissues were retrieved for PD-L1, CD8+ TILs, and p16 analyses. PD-L1 expression was evaluated by using the validated SP142 assay on the VENTANA platform. CD8+ TILs were defined by using semiquantitative scoring. RESULTS: A total of 203 patients were analyzed. PD-L1 expression was observed in 80% of patients and was significantly associated with older age (P < 0.001). A high CD8+ TIL score (≥ 6) was significantly associated with never-smoking (P = 0.020), oral cavity cancer (P < 0.001), and stage M0 at presentation (P = 0.025). The p16 status was positive in 12% of patients. Patients with a high TIL score had a significantly longer OS (P = 0.032). Patients with PD-L1 expression of 1-49% and ≥ 50% were associated with a significantly shorter OS compared with those with PD-L1 < 1% (P = 0.027 and P = 0.011, respectively). Multivariate analysis showed that PD-L1 ≥ 50% was significantly associated with a poor OS. (HR 2.98 [95% CI 1.2-7.39]; P = 0.019.) CONCLUSIONS: A high prevalence of PD-L1 expression was observed in HNSCC using the validated SP142 assay. PD-L1 expression was associated with older age, while highly PD-L1 expression (≥ 50%) was an independent prognostic factor for poor OS in anti-PD1/PD-L1 untreated HNSCC patients. SN - 1559-131X UR - https://www.unboundmedicine.com/medline/citation/30666437/Characteristics_and_impact_of_programmed_death_ligand_1_expression_CD8+_tumor_infiltrating_lymphocytes_and_p16_status_in_head_and_neck_squamous_cell_carcinoma_ L2 - https://dx.doi.org/10.1007/s12032-018-1241-1 DB - PRIME DP - Unbound Medicine ER -